Johnson & Johnson cash flow to debt ratio of 51.18% indicates that the company generates enough cash to cover its debts. This level indicates strong financial health.

Johnson & Johnson's free cash flow has decreased 0.73% from $19.84B last year to $19.70B, signaling decreasing performance

Johnson & Johnson's debt to equity ratio is 0.58, which means that the company's assets are healthy financed, signaling financial stability.

Johnson & Johnson's debt has increased relative to shareholder equity from 0.51 last year to 0.58 today, signaling weakened financials

Johnson & Johnson has a net debt to EBITDA ratio of 0.68x, which is below the 3.00x threshold, indicating healthy leverage and financial stability

Johnson & Johnson earns at least as much interest as it pays. Interest obligations are fully covered.

Johnson & Johnson's profit margin was 15.84% last year and is 21.48% this year, signaling increasing performance

Johnson & Johnson's short-term assets of $55.62B exceed its short-term liabilities of $54.13B

Johnson & Johnson's return on assets of 10.46% is higher than the 5.00% threshold, indicating efficient asset utilization

Johnson & Johnson's return on equity of 25.74%, is higher than 15.00%, indicating good performance

Johnson & Johnson's operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

Johnson & Johnson had positive net income in 5 out of 5 years, indicating stable and consistent earnings

Johnson & Johnson has positive free cash flow, indicating the company generates cash after capital expenditures

Johnson & Johnson has a free cash flow yield of 3.03%, which is above the 2.00% threshold, indicating strong cash generation relative to market value

Johnson & Johnson's yearly earnings has increased 90.56% since last year from $14.07B to $26.80B, signaling increasing performance

Johnson & Johnson's yearly revenue has increased 6.05% since last year from $88.82B to $94.19B, signaling increasing performance

ROIC 13.89% (Source: FMP key-metrics). At or above the 10% threshold. Score: 2 of 2. The company is generating returns above the upper end of the typical US weighted-average cost of capital range under this definition of invested capital.

Johnson & Johnson's 3-year revenue CAGR of 5.60% is positive, indicating growing revenue over the past 3 years

Johnson & Johnson had revenue growth in 4 out of 5 years, indicating consistent revenue performance

Johnson & Johnson had positive ROE in 5 out of 5 years, indicating consistent and reliable returns on equity

Johnson & Johnson is overvalued relative to its fair value price of 81.49 based on Base Cash Flow Valuation (DCF) model

Johnson & Johnson has an earnings yield of 3.20%, which is below the 4.00% threshold, indicating the stock may be expensive relative to its earnings

Johnson & Johnson is overvalued relative to its fair value price of 106.84 based on Base EBITDA Valuation model

Johnson & Johnson has an EV/EBITDA ratio of 16.50x, which is below the 20.00x threshold, indicating reasonable valuation relative to its operating earnings

Johnson & Johnson is overvalued relative to its fair value price of 138.07 based on Base Earnings Fair Value model

Johnson & Johnson has a PEG-ratio over 1 which is considered overvalued

Johnson & Johnson has a price-to-book ratio of 7.74x, which exceeds the 5.00x threshold, indicating the stock may be overvalued relative to its book value

Johnson & Johnson has a price-to-sales ratio of 6.71x, which is below the 8.00x threshold, indicating reasonable valuation relative to its revenue